Canopy Growth Corporation (CGC)
NASDAQ: CGC · Real-Time Price · USD
1.090
0.00 (0.00%)
At close: May 13, 2026, 4:00 PM EDT
1.097
+0.007 (0.67%)
After-hours: May 13, 2026, 5:09 PM EDT
Canopy Growth Revenue
Canopy Growth had revenue of 74.54M CAD in the quarter ending December 31, 2025, a decrease of -0.29%. This brings the company's revenue in the last twelve months to 278.39M, up 0.59% year-over-year. In the fiscal year ending March 31, 2025, Canopy Growth had annual revenue of 269.00M, down -9.47%.
Revenue (ttm)
278.39M CAD
Revenue Growth
+0.59%
P/S Ratio
2.06
Revenue / Employee
289,989 CAD
Employees
960
Market Cap
419.06M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 269.00M | -28.15M | -9.47% |
| Mar 31, 2024 | 297.15M | -36.11M | -10.83% |
| Mar 31, 2023 | 333.25M | -142.45M | -29.94% |
| Mar 31, 2022 | 475.70M | -70.95M | -12.98% |
| Mar 31, 2021 | 546.65M | 147.88M | 37.08% |
| Mar 31, 2020 | 398.77M | 172.43M | 76.18% |
| Mar 31, 2019 | 226.34M | 148.39M | 190.37% |
| Mar 31, 2018 | 77.95M | 38.05M | 95.38% |
| Mar 31, 2017 | 39.90M | 27.20M | 214.16% |
| Mar 31, 2016 | 12.70M | 10.33M | 435.60% |
| Mar 31, 2015 | 2.37M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 858.28M |
| Emergent BioSolutions | 676.80M |
| Organogenesis Holdings | 514.70M |
| Esperion Therapeutics | 418.24M |
| Ironwood Pharmaceuticals | 361.51M |
| Evolus | 301.79M |
| Akebia Therapeutics | 232.40M |
| Kamada | 180.46M |
CGC News
- 6 days ago - Canopy Growth, Spectrum expand Minor Cannabinoid softgel lineup - TheFly
- 6 days ago - Canopy Growth and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing Options - Business Wire
- 13 days ago - 3 Canadian Marijuana Stocks That Could Benefit From U.S. Reform - MarijuanaStocks
- 16 days ago - Canopy Growth Stock Is Jumping. Is It Overdue for a Much Bigger Rally? - The Motley Fool
- 18 days ago - Canopy Growth Is Rallying Again. But Is It a Dead Cat Bounce? - The Motley Fool
- 19 days ago - Akanda Shares Soar As Cannabis Stocks Rise On US Policy Change - Benzinga
- 19 days ago - 'Big Business Opportunity': Cannabis CEO Celebrates DOJ Easing Regulations On Medical Marijuana - Forbes
- 20 days ago - The cannabis rescheduling is causing celebration — and confusion — as marijuana stocks sell off - Market Watch